Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Registry for Adolescent and Pediatric Subjects Treated With Gilead HCV Direct-Acting Antivirals
2014-004674-42Phase 4Unknown
- Sponsor
- Gilead Sciences
- Start
- Aug 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sofosbuvir, ledipasvir, velpatasvir, sofosbuvir + velpatasvir + voxilaprevir, ribavirin and 1 more in hepatitis C virus infection, sponsored by Gilead Sciences. Status: unknown.
02
Drugs
sofosbuvirledipasvirvelpatasvirsofosbuvir + velpatasvir + voxilaprevirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2014-004674-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004674-42.